The development of a tumor‐associated autoantibodies panel to predict clinical outcomes for immune checkpoint inhibitor‐based treatment in patients with advanced non‐small‐cell lung cancer

BACKGROUND: Immune checkpoint inhibitors (ICIs) have become one important therapeutic strategy for advanced non‐small‐cell lung cancer (NSCLC). It remains imperative to identify reliable and convenient biomarkers to predict both the efficacy and toxicity of immunotherapy, and tumor‐associated autoan...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Jing, Wu, Yang, Yue, Yuan, Chen, Minjiang, Xu, Yan, Liu, Xiangning, Liu, Xiaoyan, Gao, Xiaoxing, Wang, Hanping, Si, Xiaoyan, Zhong, Wei, Zhang, Xiaotong, Zhang, Li, Wang, Mengzhao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9925345/
https://www.ncbi.nlm.nih.gov/pubmed/36594104
http://dx.doi.org/10.1111/1759-7714.14772

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9925345/
https://www.ncbi.nlm.nih.gov/pubmed/36594104
http://dx.doi.org/10.1111/1759-7714.14772

Ejemplares similares